1. GPCR/G Protein
  2. mGluR

L-Glutamine (Synonyms: L-Glutamic acid 5-amide)

Cat. No.: HY-N0390 Purity: >98.0%
Data Sheet SDS Handling Instructions

L-Glutamine is a non-essential amino acid present abundantly throughout the body and is involved in gastrointestinal disorders.

For research use only. We do not sell to patients.
L-Glutamine Chemical Structure

L-Glutamine Chemical Structure

CAS No. : 56-85-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in Water $55 In-stock
100 mg $50 In-stock
500 mg $80 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of L-Glutamine:

  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

L-Glutamine is a non-essential amino acid present abundantly throughout the body and is involved in gastrointestinal disorders. Target: mGluR Glutamine (abbreviated as Gln or Q) is one of the 20 amino acids encoded by the standard genetic code. It is not recognized as an essential amino acid, but may become conditionally essential in certain situations, including intensive athletic training or certain gastrointestinal disorders. Its side-chain is an amide formed by replacing the side-chain hydroxyl of glutamic acid with an amine functional group, making it the amide of glutamic acid. Its codons are CAA and CAG. In human blood, glutamine is the most abundant free amino acid, with a concentration of about 500-900 μmol/L. Glutamine is synthesized by the enzyme glutamine synthetase from glutamate and ammonia. The most relevant glutamine-producing tissue is the muscle mass, accounting for about 90% of all glutamine synthesized. Glutamine is also released, in small amounts, by the lung and the brain. Although the liver is capable of relevant glutamine synthesis, its role in glutamine metabolism is more regulatory than producing, since the liver takes up large amounts of glutamine derived from the gut. The most eager consumers of glutamine are the cells of intestines, the kidney cells for the acid-base balance, activated immune cells, and manycancer cells. In respect to the last point mentioned, different glutamine analogues, such as DON, Azaserine or Acivicin, are tested as anticancer drugs.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02215083 Eastern Regional Medical Center|TSPC America, Inc. Peripheral Neuropathy August 2014 Phase 1
NCT00125788 Emmaus Medical, Inc.|FDA Office of Orphan Products Development Sickle Cell Anemia|Thalassemia March 2004 Phase 2
NCT00586209 Los Angeles Biomedical Research Institute|Emmaus Medical, Inc. Sickle Cell Anemia|Thalassemia January 2003 Phase 2
NCT02838979 University of Washington|New York Medical College|Emory University|Vanderbilt University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cardiovascular Disease|Sarcopenia|Endothelial Dysfunction|Muscle Mitochondrial Function|Kidney Disease July 2015 Phase 2
NCT00006994 Southwest Oncology Group|National Cancer Institute (NCI) Cancer-related Problem/Condition|Head and Neck Cancer|Pain November 2001 Phase 3
NCT01179217 Emmaus Medical, Inc. Sickle Cell Anemia|Sickle ß0-Thalassemia May 2010 Phase 3
NCT01048905 Children's Hospital & Research Center Oakland Pulmonary Hypertension|Sickle Cell Disease|Thalassemia March 2009 Phase 2
NCT01478126 Meshalkin Research Institute of Pathology of Circulation Coronary Artery Disease January 2012 Phase 3
NCT00296621 Assistance Publique - Hôpitaux de Paris Muscular Dystrophy, Duchenne February 2006 Phase 2
NCT02053350 University of Virginia Clostridium Difficile Infection April 2015 Phase 2
NCT01832636 Children's Hospital Medical Center, Cincinnati|Universidade Federal do Ceara Malnutrition|Environmental Enteropathy|Diarrhea October 2013 Phase 3
NCT01353638 Christoph Aufricht|Medical University of Vienna End Stage Renal Disease April 2011 Phase 1|Phase 2
NCT00922688 Medical Center Alkmaar Colon Carcinoma December 2010
NCT00647036 Institute of Child Health Surgical Infants Requiring Total Parenteral Nutrition July 2008 Phase 4
NCT00338221 University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID) Diarrhea, Malnutrition August 2004 Phase 3
NCT00133562 University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID) Diarrhea, Malnutrition|Other Nutritional Deficiencies August 2004 Phase 3
NCT01092039 Xigo Health LLC Common Cold March 2010
View MoreCollapse
References
Molecular Weight

146.14

Formula

C₅H₁₀N₂O₃

CAS No.

56-85-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 40 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
L-Glutamine
Cat. No.:
HY-N0390
Quantity: